Rare condition

Interstitial lung disease due to SP-C deficiency

0

studies recruiting now

as of 7 Sept 2026

0

studies registered in total

as of 7 Sept 2026

0

countries with a recruiting site

as of 7 Sept 2026

None

recruiting study posted to date

among recruiting studies

Recruiting trials

No registered studies found for Interstitial lung disease due to SP-C deficiency.

ClinicalTrials.gov has no study listed under this name as of 7 Sept 2026. That can change, and there are other routes worth knowing about.

Keep watching

Get an email when a new Interstitial lung disease due to SP-C deficiency study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

About Interstitial lung disease due to SP-C deficiency

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (SFTPC).

Treatments being studied

2 approved treatments and 18 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Nintedanib (Nintedanib component of ofev)Approved: Nintedanib Esylate (Nintedanib accord)
Phase 3Fentanyl Citrate (Abstral)
Phase 3Mycophenolate Mofetil (Arzip)
Phase 3Treprostinil (Remodulin)
Phase 3Pirfenidone (Esbriet)
Phase 3Belimumab (Benlysta)
Phase 3Tadalafil (Adcirca)
Phase 3Rituximab (Blitzima)
Phase 3Nerandomilast

+ 10 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).